- Fibroblast growth factor receptor 3 (FGFR3) alteration is associated with lower responses to platinum-based chemotherapy in patients with muscle-invasive bladder cancer (MIBC).
- This relationship, however, was not observed in metastatic disease.
Why this matters
- FGFR3 status can help in treatment decision-making in bladder cancer.
- The study included:
- 72 patients with MIBC treated with cisplatin-based neoadjuvant chemotherapy (NAC).
- 108 patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy at Memorial Sloan Kettering Cancer Center.
- 253 patients from The Cancer Genome Atlas (TCGA) bladder cancer cohort.
- Funding: National Cancer Institute.
- NAC cohort:
- 13% of patients had FGFR3 alteration, none of whom had pathologic complete response; 3 had residual non-MIBC.
- FGFR3 alteration was associated with shorter recurrence-free survival (RFS; HR, 2.74; P=.044) but not OS.
- TCGA cohort:
- Among patients who underwent adjuvant chemotherapy, those with FGFR3 alteration had shorter RFS (HR, 7.27; P<.001>
- In chemotherapy-naive patients, FGFR3 alteration was associated with longer RFS (P=.0073).
- FGFR3 alteration was associated with higher rates of pulmonary metastasis (47% vs 30%; P=.024) and extrapelvic lymphadenopathy (75% vs 62%; P=.038).
- FGFR3 alteration showed no association with survival.